TY - JOUR
T1 - Adherence to quality indicators in chronic myeloid leukemia care
T2 - results from a population-based study in The Netherlands
AU - Ector, Geneviève I.C.G.
AU - Geelen, Inge G.P.
AU - Dinmohamed, Avinash G.
AU - Hoogendoorn, Mels
AU - Westerweel, Peter E.
AU - Hermens, Rosella P.M.G.
AU - Blijlevens, Nicole M.A.
N1 - Funding:
An educational grant by BMS and Novartis was received by
P.E. Westerwe
Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Suboptimal guideline adherence in chronic myeloid leukemia (CML) care is associated with worse treatment outcomes. Current study focused on adherence to seven quality indicators (QIs) based on the European Leukemia Network guideline (one diagnostic, one therapeutic, and five monitoring indicators). Data were obtained from population-based registries in the Netherlands of 405 newly diagnosed chronic phase CML patients between January 2008 and April 2013. Compliance rates regarding diagnostic and therapeutic indicator were 83% and 78%, respectively. Monitoring indicators rates were lower: 21–27% for indicators concerning the first year and 58% and 62% for the second and third year, respectively. Noncompliance occurred mostly due to non-timely monitoring. Twenty cases did not comply with any indicator, 6% complied with all indicators. After adjustment for age, overall survival rates did not differ significantly between the groups. Adherence to guideline-based QIs was suboptimal. This demonstrates the evidence-practice gap, shows room for improvement and underscores the need for real-world data.
AB - Suboptimal guideline adherence in chronic myeloid leukemia (CML) care is associated with worse treatment outcomes. Current study focused on adherence to seven quality indicators (QIs) based on the European Leukemia Network guideline (one diagnostic, one therapeutic, and five monitoring indicators). Data were obtained from population-based registries in the Netherlands of 405 newly diagnosed chronic phase CML patients between January 2008 and April 2013. Compliance rates regarding diagnostic and therapeutic indicator were 83% and 78%, respectively. Monitoring indicators rates were lower: 21–27% for indicators concerning the first year and 58% and 62% for the second and third year, respectively. Noncompliance occurred mostly due to non-timely monitoring. Twenty cases did not comply with any indicator, 6% complied with all indicators. After adjustment for age, overall survival rates did not differ significantly between the groups. Adherence to guideline-based QIs was suboptimal. This demonstrates the evidence-practice gap, shows room for improvement and underscores the need for real-world data.
UR - http://www.scopus.com/inward/record.url?scp=85142158491&partnerID=8YFLogxK
U2 - 10.1080/10428194.2022.2142055
DO - 10.1080/10428194.2022.2142055
M3 - Article
C2 - 36369821
AN - SCOPUS:85142158491
SN - 1042-8194
VL - 64
SP - 424
EP - 432
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -